Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an unrestricted educational grant from Amarin Pharma, Inc.
Target Audience: The intended audience for this activity is cardiologists and other health care professionals involved in the treatment of patients with residual risk and hypertriglyceridemia.
Learning Objectives: Upon successful completion of this activty, participants should be better able to:
- Review recent clinical evidence about residual risk in high-risk patients and its contribution toward the development and progression of atherosclerosis as well as increased cardiovascular events.
- Examine new evidence-based recommendations and guidelines for the management of dyslipidemias.
- Assess new findings that suggest improved residual risk management beyond LDL-C control, in both primary and secondary prevention.
Activity Chair:
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine
Harvard Medical School
Boston, MA
Faculty:
Christie M. Ballantyne, MD
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX
Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology, and Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Cardiology Division
Baltimore, MD
Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 4, 2019 to January 3, 2020.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty members report the following relationships:
Christie M. Ballantyne, MD
Consulting Fee: Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Denka Seiken, Eli Lilly, Esperion, Gilead, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Contracted Research (paid to institution): Abbott Diagnostics, ADA, AHA, Akcea, Amarin, Amgen, Esperion, NIH, Novartis, Regeneron, Roche Diagnostic, Sanofi-Synthelabo
Deepak L. Bhatt, MD, MPH
Contracted Research: Abbott Medical Optics, Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, PhaseBio, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company
Michael Miller, MD, FACC, FAHA
No relevant financial relationships to disclose.
Reviewers report the following relationship(s):
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com